Question explored with the scientific record
Conversation so far
- 1 \what is known about CBD (broad spectrum or isolate) and CBN for sleep
- 2 how about high dose cbd
Answered on this page ↓
how about high dose cbd
The short version: high-dose CBD is where the real side effects live, and the sleep evidence at high dose is thin and mixed.
The dose question matters because CBD's harms scale with dose. A meta-analysis of randomized trials found any-adverse-event risk rose with dose, and the liver signal was concentrated in high-dose trials above 20 mg/kg/day, mostly in childhood epilepsy [1]. Withdrawal from trials for any reason was about 2.6 times more likely on CBD, and serious adverse events roughly 2.3 times more likely, driven by the epilepsy group [1]. Outside epilepsy, serious events were rare [1].
For sleep specifically, the one high-dose trial here is a combination, not CBD alone: 200 mg CBD plus 10 mg THC in insomnia patients actually reduced total sleep time by about 24 minutes and cut REM sleep, versus placebo [2]. That is the opposite of what people buy it for. The high-dose epilepsy data show real seizure benefit in a severe pediatric population [3], but that is a different disease and a different risk calculus.
| Finding | High-dose CBD | Source |
|---|---|---|
| Any adverse event | 67.6% vs 54.5% placebo | [1] |
| Abnormal liver tests | 21 events, all CBD groups | [1] |
| Withdrawal, any reason | ~2.6x placebo | [1] |
| Sleep time (200mg CBD+10mg THC) | -24.5 min vs placebo | [2] |
What this evidence cannot see: no trial here tests high-dose CBD alone for sleep in healthy adults. That gap is real, and it is the study that would settle it.
My call: high-dose CBD is not a sleep aid I would recommend, and the dose-dependent liver and dropout signals are the reason to be cautious, not the marketing. Confidence: moderate.
Sources used 3
-
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
A comprehensive systematic review and meta-analysis of randomized, placebo-controlled trials assessing adverse effects of cannabidiol (CBD) across indications, finding CBD increases withdrawals and adverse events—driven largely by high-dose CBD in childhood epilepsy with notable…
DOI: 10.1038/s41386-020-0667-2 -
O006 Acute effects of combined cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG
In adults with insomnia disorder, a within-subject randomized two-period trial comparing a single oral dose of CBD/THC (200 mg CBD + 10 mg THC) to placebo showed reduced total sleep time and REM sleep, increased REM latency, modest next-day effects with no cognitive impairment, …
DOI: 10.1093/sleepadvances/zpac029.005 -
Long-Term Evaluation of Cannabidiol in Pediatric Drug-Resistant Epilepsy: A Real-Time Single-Center Retrospective Study
Real-world, single-center pediatric Lennox-Gastaut syndrome treated with long-term cannabidiol shows meaningful seizure reduction and tolerability, with seven patients achieving seizure freedom after 24 months and about half remaining on CBD at 24 months.
DOI: 10.26815/acn.2025.00997